In the light of these conflicting reports, we analyzed SSTR2 expression by immunohistochemistry on a large (3,261 tumors) prostate cancer tissue microarray (TMA) and by publicly available Gene Expression Omnibus (GEO) datasets of human prostate cancer gene expression arrays in order to comprehensively clarify prevalence and clinical significance of SSTR2 expression in prostate cancers. Here, SSTR2 is linked to prostate carcinoma.